Market Cap$44.20B
P/E41.67x
PEG Ratio2.89
Div yield—
Beta1.55
IDXX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-13.96%
Price vs S&P 500 (4W)10.07%
PEG Ratio2.89
VGM Score53.34
P/E Ratio (Annual)41.67x
IDXX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $3.93 | $4.27 | +8.54%(+$0.34) | |
| Q1 2026 | $3.41 | $3.47 | +1.74%(+$0.06) | |
| Q4 2025 | $2.94 | $3.08 | +4.81%(+$0.14) | |
| Q3 2025 | $3.15 | $3.40 | +8.08%(+$0.25) | |
| Q2 2025 | $3.30 | $3.63 | +9.97%(+$0.33) |
IDXX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.95
3.95
3.95
3.95
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
IDXXIdexx Laboratories Inc | D | B | B | 9.7x | 12.8% | 62.5% | 14.3% | $560.36 |
| LNTHLantheus Holdings, Inc | C | B | B | 4.2x | 2.4% | 61.0% | 40.7% | $99.70 |
| NEOGNeogen Corp | C | C | A | 2.9x | -0.3% | 47.4% | — | $11.81 |
| CLDXCelldex Therapeutics, Inc | F | F | C | 13683.0x | -97.3% | 17.6% | — | $27.53 |
| NTLAIntellia Therapeutics, Inc | D | D | C | 26.9x | 12.6% | — | — | $11.42 |
| QDELQuidelOrtho Corporation Common Stock | C | C | C | 0.3x | -2.5% | 44.6% | — | $12.91 |
| ACHVAchieve Life Sciences, Inc. | F | F | B | 36.8x | -89.3% | — | — | $6.38 |
| MYGNMyriad Genetics Inc | C | C | D | 0.5x | -3.2% | 68.8% | — | $3.98 |
| TKNOAlpha Teknova, Inc. Common Stock | D | C | B | 8.7x | 12.3% | 34.6% | — | $7.08 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | C | F | 34.0x | -5.7% | 89.0% | — | $3.13 |
| IMDXInsight Molecular Diagnostics Inc. Common Stock | F | D | C | 59.0x | -60.8% | 48.3% | — | $3.01 |
About Idexx Laboratories Inc
IDEXX Laboratories is a leading provider of diagnostic solutions and practice management software for veterinary and livestock producers. The company offers in-clinic diagnostic test kits, laboratory analyzers, reference laboratory services, and veterinary practice management software that enable disease detection and management. With approximately 35% of revenues derived outside the United States, IDEXX operates across both domestic and international veterinary markets.